BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 21999454)

  • 1. Diet and colorectal cancer: analysis of a candidate pathway using SNPS, haplotypes, and multi-gene assessment.
    Slattery ML; Lundgreen A; Herrick JS; Caan BJ; Potter JD; Wolff RK
    Nutr Cancer; 2011 Nov; 63(8):1226-34. PubMed ID: 21999454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: mTOR, PTEN, STK11, RPKAA1, PRKAG2, TSC1, TSC2, PI3K and Akt1.
    Slattery ML; Herrick JS; Lundgreen A; Fitzpatrick FA; Curtin K; Wolff RK
    Carcinogenesis; 2010 Sep; 31(9):1604-11. PubMed ID: 20622004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic variation in RPS6KA1, RPS6KA2, RPS6KB1, RPS6KB2, and PDK1 and risk of colon or rectal cancer.
    Slattery ML; Lundgreen A; Herrick JS; Wolff RK
    Mutat Res; 2011 Jan; 706(1-2):13-20. PubMed ID: 21035469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes.
    Wang LE; Ma H; Hale KS; Yin M; Meyer LA; Liu H; Li J; Lu KH; Hennessy BT; Li X; Spitz MR; Wei Q; Mills GB
    J Cancer Res Clin Oncol; 2012 Mar; 138(3):377-85. PubMed ID: 22146979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy.
    Hildebrandt MA; Yang H; Hung MC; Izzo JG; Huang M; Lin J; Ajani JA; Wu X
    J Clin Oncol; 2009 Feb; 27(6):857-71. PubMed ID: 19164214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Gene Expression Status of the PI3K/AKT/mTOR Pathway in Gastric Cancer Tissues and Cell Lines.
    Riquelme I; Tapia O; Espinoza JA; Leal P; Buchegger K; Sandoval A; Bizama C; Araya JC; Peek RM; Roa JC
    Pathol Oncol Res; 2016 Oct; 22(4):797-805. PubMed ID: 27156070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic Database Analysis for Head and Neck Cancer Prevention Targets: MTOR Signal Transduction Pathway.
    Koenigsberg C; Ondrey FG
    Anticancer Res; 2020 Oct; 40(10):5417-5421. PubMed ID: 32988862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Livers with constitutive mTORC1 activity resist steatosis independent of feedback suppression of Akt.
    Kenerson HL; Subramanian S; McIntyre R; Kazami M; Yeung RS
    PLoS One; 2015; 10(2):e0117000. PubMed ID: 25646773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy.
    Pu X; Hildebrandt MA; Lu C; Lin J; Stewart DJ; Ye Y; Gu J; Spitz MR; Wu X
    Lung Cancer; 2011 Jan; 71(1):82-8. PubMed ID: 20447721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GSK3 and its interactions with the PI3K/AKT/mTOR signalling network.
    Hermida MA; Dinesh Kumar J; Leslie NR
    Adv Biol Regul; 2017 Aug; 65():5-15. PubMed ID: 28712664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Swimming exercise training-induced left ventricular hypertrophy involves microRNAs and synergistic regulation of the PI3K/AKT/mTOR signaling pathway.
    Ma Z; Qi J; Meng S; Wen B; Zhang J
    Eur J Appl Physiol; 2013 Oct; 113(10):2473-86. PubMed ID: 23812090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of genetic variations in the PI3K/PTEN/AKT/mTOR pathway in Korean patients with colorectal cancer.
    Kim JG; Chae YS; Sohn SK; Kang BW; Moon JH; Lee SJ; Jeon SW; Park JS; Park JY; Choi GS
    Oncology; 2010; 79(3-4):278-82. PubMed ID: 21412012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation in activation and expression of phosphatase and tensin homolog on chromosome ten, Akt1, and 3-phosphoinositide-dependent kinase 1: further evidence demonstrating altered phosphoinositide 3-kinase signaling in postmortem brain of suicide subjects.
    Dwivedi Y; Rizavi HS; Zhang H; Roberts RC; Conley RR; Pandey GN
    Biol Psychiatry; 2010 Jun; 67(11):1017-25. PubMed ID: 20163786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer.
    Vasudevan KM; Barbie DA; Davies MA; Rabinovsky R; McNear CJ; Kim JJ; Hennessy BT; Tseng H; Pochanard P; Kim SY; Dunn IF; Schinzel AC; Sandy P; Hoersch S; Sheng Q; Gupta PB; Boehm JS; Reiling JH; Silver S; Lu Y; Stemke-Hale K; Dutta B; Joy C; Sahin AA; Gonzalez-Angulo AM; Lluch A; Rameh LE; Jacks T; Root DE; Lander ES; Mills GB; Hahn WC; Sellers WR; Garraway LA
    Cancer Cell; 2009 Jul; 16(1):21-32. PubMed ID: 19573809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endometrial cancer and genetic variation in PTEN, PIK3CA, AKT1, MLH1, and MSH2 within a population-based case-control study.
    Lacey JV; Yang H; Gaudet MM; Dunning A; Lissowska J; Sherman ME; Peplonska B; Brinton LA; Healey CS; Ahmed S; Pharoah P; Easton D; Chanock S; Garcia-Closas M
    Gynecol Oncol; 2011 Feb; 120(2):167-73. PubMed ID: 21093899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanism.
    Yu S; Shen G; Khor TO; Kim JH; Kong AN
    Mol Cancer Ther; 2008 Sep; 7(9):2609-20. PubMed ID: 18790744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase.
    Roux PP; Ballif BA; Anjum R; Gygi SP; Blenis J
    Proc Natl Acad Sci U S A; 2004 Sep; 101(37):13489-94. PubMed ID: 15342917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors.
    Xu G; Zhang W; Bertram P; Zheng XF; McLeod H
    Int J Oncol; 2004 Apr; 24(4):893-900. PubMed ID: 15010827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The p53 target Plk2 interacts with TSC proteins impacting mTOR signaling, tumor growth and chemosensitivity under hypoxic conditions.
    Matthew EM; Hart LS; Astrinidis A; Navaraj A; Dolloff NG; Dicker DT; Henske EP; El-Deiry WS
    Cell Cycle; 2009 Dec; 8(24):4168-75. PubMed ID: 20054236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell type specificity of PI3K signaling in Pdk1- and Pten-deficient brains.
    Chalhoub N; Zhu G; Zhu X; Baker SJ
    Genes Dev; 2009 Jul; 23(14):1619-24. PubMed ID: 19605683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.